Suppr超能文献

呼吁在审查证据时进行更严谨的学术研究:以乳腺钼靶筛查为例。

A plea for more careful scholarship in reviewing evidence: the case of mammographic screening.

作者信息

Duffy Stephen W, Tabar Laszlo, Chen Tony H H, Yen Amy M F, Dean Peter B, Smith Robert A

机构信息

Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, London, UK.

Falun Central Hospital, Falun, Sweden.

出版信息

BJR Open. 2023 Sep 25;5(1):20230041. doi: 10.1259/bjro.20230041. eCollection 2023.

Abstract

OBJECTIVES

To identify issues of principle and practice giving rise to misunderstandings in reviewing evidence, to illustrate these by reference to the Nordic Cochrane Review (NCR) and its interpretation of two trials of mammographic screening, and to draw lessons for future reviewing of published results.

METHODS

A narrative review of the publications of the Nordic Cochrane Review of mammographic screening (NCR), the Swedish Two-County Trial (S2C) and the Canadian National Breast Screening Study 1 and 2 (CNBSS-1 and CNBSS-2).

RESULTS

The NCR concluded that the S2C was unreliable, despite the review's complaints being shown to be mistaken, by direct reference to the original primary publications of the S2C. Repeated concerns were expressed by others about potential subversion of randomisation in CNBSS-1 and CNBSS-2; however, the NCR continued to rely heavily on the results of these trials. Since 2022, however, eyewitness evidence of such subversion has been in the public domain.

CONCLUSIONS

An over-reliance on nominal satisfaction of checklists of criteria in systematic reviewing can lead to erroneous conclusions. This occurred in the case of the NCR, which concluded that mammographic screening was ineffective or minimally effective. Broader and more even-handed reviews of the evidence show that screening confers a substantial reduction in breast cancer mortality.

ADVANCES IN KNOWLEDGE

Those carrying out systematic reviews should be aware of the dangers of over-reliance on checklists and guidelines. Readers of systematic reviews should be aware that a systematic review is just another study, with the capability that all studies have of coming to incorrect conclusions. When a review seems to overturn the current position, it is essential to revisit the publications of the primary research.

摘要

目的

识别在证据审查中引发误解的原则和实践问题,通过参考北欧Cochrane系统评价(NCR)及其对两项乳腺钼靶筛查试验的解读来说明这些问题,并为未来已发表结果的审查吸取经验教训。

方法

对北欧Cochrane系统评价乳腺钼靶筛查(NCR)、瑞典双县试验(S2C)以及加拿大国家乳腺筛查研究1和2(CNBSS - 1和CNBSS - 2)的相关出版物进行叙述性综述。

结果

尽管通过直接参考S2C的原始主要出版物表明该综述的投诉是错误的,但NCR仍得出S2C不可靠的结论。其他人多次对CNBSS - 1和CNBSS - 2中随机化可能被破坏表示担忧;然而,NCR仍严重依赖这些试验的结果。然而,自2022年以来,这种破坏行为的目击证据已公之于众。

结论

在系统评价中过度依赖标准清单表面上的满足情况可能导致错误结论。NCR的情况就是如此,其得出乳腺钼靶筛查无效或效果甚微的结论。对证据进行更广泛、更公正的审查表明,筛查可大幅降低乳腺癌死亡率。

知识进展

进行系统评价的人员应意识到过度依赖清单和指南的风险。系统评价的读者应意识到,系统评价只是另一项研究,与所有研究一样都有可能得出错误结论。当一项综述似乎推翻当前立场时,重新审视原始研究的出版物至关重要。

相似文献

1
A plea for more careful scholarship in reviewing evidence: the case of mammographic screening.
BJR Open. 2023 Sep 25;5(1):20230041. doi: 10.1259/bjro.20230041. eCollection 2023.
3
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Conclusions for mammography screening after 25-year follow-up of the Canadian National Breast Cancer Screening Study (CNBSS).
Eur Radiol. 2016 Feb;26(2):342-50. doi: 10.1007/s00330-015-3849-2. Epub 2015 May 28.
6
Errors in Conduct of the CNBSS Trials of Breast Cancer Screening Observed by Research Personnel.
J Breast Imaging. 2022 Apr 15;4(2):135-143. doi: 10.1093/jbi/wbac009.
7
8
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
9

引用本文的文献

1
Noncancer-Related Mortality in Randomized Clinical Trials: A Meta-Analysis.
JAMA Netw Open. 2025 Aug 1;8(8):e2526990. doi: 10.1001/jamanetworkopen.2025.26990.

本文引用的文献

2
The randomized trial of mammography screening that was not-A cautionary tale.
J Med Screen. 2022 Mar;29(1):7-11. doi: 10.1177/09691413211059461. Epub 2021 Nov 23.
3
The current status of risk-stratified breast screening.
Br J Cancer. 2022 Mar;126(4):533-550. doi: 10.1038/s41416-021-01550-3. Epub 2021 Oct 26.
5
The Evaluation of Cancer Screening: Concepts and Outcome Measures.
Med Clin North Am. 2020 Nov;104(6):939-953. doi: 10.1016/j.mcna.2020.07.002. Epub 2020 Sep 17.
6
Breast Cancer Screening and Diagnosis.
Ann Intern Med. 2020 Jun 16;172(12):838-839. doi: 10.7326/L20-0253.
7
Breast Cancer Screening and Diagnosis.
Ann Intern Med. 2020 Jun 16;172(12):840-841. doi: 10.7326/L20-0254.
8
Systematic reviews as a "lens of evidence": Determinants of participation in breast cancer screening.
J Med Screen. 2021 Jun;28(2):70-79. doi: 10.1177/0969141320930743. Epub 2020 Jun 9.
9
Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines.
Ann Intern Med. 2020 Jan 7;172(1):46-56. doi: 10.7326/M19-2125. Epub 2019 Nov 26.
10
Quality-of-life effects of screening mammography in Norway.
Int J Cancer. 2020 Apr 15;146(8):2104-2112. doi: 10.1002/ijc.32539. Epub 2019 Sep 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验